Iris Tavor
Consigliere Generale presso ENLIVEX THERAPEUTICS LTD.
Profilo
Iris Tavor is currently a Senior Director of Regulatory and Quality Affairs at Enlivex Therapeutics Ltd.
She previously worked as the Head of Quality and Regulatory Affairs at Pluristem Ltd.
Posizioni attive di Iris Tavor
| Società | Posizione | Inizio |
|---|---|---|
| ENLIVEX THERAPEUTICS LTD. | Consigliere Generale | - |
Precedenti posizioni note di Iris Tavor
| Società | Posizione | Fine |
|---|---|---|
Pluristem Ltd.
 Pluristem Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Pluri, Inc., Pluristem Ltd. is an Israeli company that sources therapeutic cells from the placenta to create cell-based products for commercial use. The company is based in Haifa, Israel and was founded by Yoram Nathan Drucker. The company's patented and validated 3D cell expansion system is designed to mimic the human body, and its cell therapies have potentially groundbreaking applications for treating ischemia, damaged muscle, hematology deficiencies, and inflammation. Pluristem's method is uniquely accurate, cost-effective, and consistent from batch to batch. Pluristem was acquired by Pluri, Inc. on June 23, 2003. | Consigliere Generale | - |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ENLIVEX THERAPEUTICS LTD. | Health Technology |
| Aziende private | 1 |
|---|---|
Pluristem Ltd.
Pluristem Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Pluri, Inc., Pluristem Ltd. is an Israeli company that sources therapeutic cells from the placenta to create cell-based products for commercial use. The company is based in Haifa, Israel and was founded by Yoram Nathan Drucker. The company's patented and validated 3D cell expansion system is designed to mimic the human body, and its cell therapies have potentially groundbreaking applications for treating ischemia, damaged muscle, hematology deficiencies, and inflammation. Pluristem's method is uniquely accurate, cost-effective, and consistent from batch to batch. Pluristem was acquired by Pluri, Inc. on June 23, 2003. | Commercial Services |
- Borsa valori
- Insiders
- Iris Tavor
